Activation of type II NADH dehydrogenase by Quinolinequinones mediates antitubercular cell death

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 10, 2016, Pages 2840-2847

  Heikal, Adam ^a,b   Hards, Kiel ^a   Cheung, Chen Yi ^a   Menorca, Ayana ^a   Timmer, Mattie S M ^c   Stocker, Bridget L ^c,d   Cook, Gregory M ^a,b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^d MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; ISONIAZID; QUINOLINE DERIVATIVE; QUINOLINEQUINONE DERIVATIVE; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; TYPE 2 REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; UNCLASSIFIED DRUG; 7-CHLORO-6-(2-CHLOROETHYLAMINO)-5,8-QUINOLINEQUINONE; BACTERIAL PROTEIN; NADH DEHYDROGENASE II; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERIAL CELL; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; ENERGY TRANSFER; ENZYME ACTIVATION; INSTRUMENT STERILIZATION; MEMBRANE VESICLE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OXIDATION; OXYGEN CONSUMPTION; OXYGEN ELECTRODE; RESPIRATORY CHAIN; DRUG DEVELOPMENT; DRUG EFFECTS; ELECTRON TRANSPORT; METABOLISM; MICROBIAL VIABILITY; OXIDATION REDUCTION REACTION; PHYSIOLOGY;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CLOFAZIMINE; DRUG DISCOVERY; ELECTRON TRANSPORT; ENZYME ACTIVATION; MICROBIAL VIABILITY; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NADH DEHYDROGENASE; OXIDATION-REDUCTION; QUINOLONES; QUINONES; REACTIVE OXYGEN SPECIES;

EID: 84994796510     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw244     Document Type: Article

References (59)

1. Bringmann G, Reichert Y, Kane VV. The total synthesis of streptonigrin and related antitumor antibiotic natural products. Tetrahedron 2004; 60: 3539-74.
2. Colucci MA, Moody CJ, Couch GD. Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential. Org Biomol Chem 2008; 6: 637-56.
3. Ibacache JA, Delgado V, Benites J et al. Synthesis, half-wave potentials and antiproliferative activity of 1-aryl-substituted aminoisoquinolinequinones. Molecules 2014; 19: 726-39.
4. Pearce AN, Chia EW, Berridge MV et al. Anti-inflammatory thiazine alkaloids isolated from the New Zealand ascidian Aplidium sp.: Inhibitors of the neutrophil respiratory burst in a model of gouty arthritis. J Nat Prod 2007; 70: 936-40.
5. Claes P, Cappoen D, Uythethofken C et al. 2, 4-Dialkyl-8, 9, 10, 11-tetrahydrobenzo[g]pyrimido[4, 5-c]isoquinoline-1, 3, 7, 12(2H, 4H)-tetraones as new leads against Mycobacterium tuberculosis. Eur J Med Chem 2014; 77: 409-21.
6. Fryatt T, Goroski DT, Nilson ZD et al. Novel quinolinequinone antitumor agents: Structure-metabolism studies with NAD(P)H:quinone oxidoreductase (NQO1). Bioorg Med Chem Lett 1999; 9: 2195-8.
7. Fryatt T, Pettersson HI, Gardipee WTet al. Novel quinolinequinone antitumor agents: structure-metabolism studies with NAD(P)H:quinone oxidoreductase (NQO1). Bioorg Med Chem 2004; 12: 1667-87.
8. Keyari CM, Kearns AK, Duncan NS et al. Synthesis of new quinolinequinone derivatives and preliminary exploration of their cytotoxic properties. J Med Chem 2013; 56: 3806-19.
9. Seow HA, Penketh PG, Baumann RP et al. Bioactivation and resistance to mitomycin C. Methods Enzymol 2004; 382: 221-33.
10. Li JZ, Ke Y, Misra HP et al. Mechanistic studies of cancer cell mitochondria-and NQO1-mediated redox activation of b-lapachone, a potentially novel anticancer agent. Toxicol Appl Pharmacol 2014; 281: 285-93.
11. Rao KV, Cullen WP. Streptonigrin, an antitumor substance. I. Isolation and characterization. Antibiot Annu 1959; 7: 950-3.
12. Rao KV, Biemann K, Woodward RB. The structure of streptonigrin. J Am Chem Soc 1963; 85: 2532-3.
13. Beall HD, Liu Y, Siegel D et al. Role of NAD(P)H:quinone oxidoreductase (DT-diaphorase) in cytotoxicity and induction of DNA damage by streptonigrin. Biochem Pharmacol 1996; 51: 645-52.
14. Mulchin BJ, Newton CG, Baty JWet al. The anti-cancer, anti-inflammatory and tuberculostatic activities of a series of 6, 7-substituted-5, 8-quinolinequinones. Bioorg Med Chem 2010; 18: 3238-51.
15. Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307: 223-7.
16. Diacon AH, Donald PR, Pym A et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012; 56: 3271-6.
17. Diacon AH, Pym A, Grobusch M et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-405.
18. Pethe K, Bifani P, Jang J et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med 2013; 19: 1157-60.
19. Sacksteder KA, Protopopova M, Barry CE 3rd et al. Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol 2012; 7: 823-37.
20. Hards K, Robson JR, Berney M et al. Bactericidal mode of action of bedaquiline. J Antimicrob Chemother 2015; 70: 2028-37.
21. Li K, Schurig-Briccio LA, Feng X et al. Multitarget drug discovery for tuberculosis and other infectious diseases. J Med Chem 2014; 57: 3126-39.
22. Yano T, Kassovska-Bratinova S, Teh JS et al. Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase a pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem 2011; 286: 10276-87.
23. Melo AMP, Bandeiras TM, Teixeira M. New insights into Type II NAD(P)H:quinone oxidoreductases. Microbiol Mol Biol R 2004; 68: 603-16.
24. Heikal A, Nakatani Y, Dunn E et al. Structure of the bacterial type II NADH dehydrogenase: a monotopic membrane protein with an essential role in energy generation. Mol Microbiol 2014; 91: 950-64.
25. Sassetti CM, Boyd DH, Rubin EJ. Genes required formycobacterial growth defined by high density mutagenesis. Mol Microbiol 2003; 48: 77-84.
26. McAdam RA, Quan S, Smith DA et al. Characterization of a Mycobacterium tuberculosis H37Rv transposon library reveals insertions in 351 ORFs and mutants with altered virulence. Microbiology 2002; 148: 2975-86.
27. Ananthan S, Faaleolea ER, Goldman RC et al. High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis (Edinb) 2009; 89: 334-53.
28. Ekins S, Kaneko T, Lipinski CA et al. Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis. Mol Biosyst 2010; 6: 2316-24.
29. Snapper SB, Melton RE, Mustafa S et al. Isolation and characterization of efficient plasmid transformation mutants of Mycobacterium smegmatis. Mol Microbiol 1990; 4: 1911-9.
30. Wang F, Jain P, Gulten G et al. Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid. Antimicrob Agents Chemother 2010; 54: 3776-82.
31. Sambandamurthy VK, Derrick SC, Hsu T et al. Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. Vaccine 2006; 24: 6309-20.
32. Bashiri G, Rehan AM, Greenwood DR et al. Metabolic engineering of cofactor F420 production in Mycobacterium smegmatis. PLoS One 2010; 5: e15803.
33. Rampersad SN. Multiple applications of Alamar Blue as an indicator of metabolic function and cellular health in cell viability bioassays. Sensors (Basel) 2012; 12: 12347-60.
34. Ritz N, Tebruegge M, Connell TG et al. Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. Antimicrob Agents Chemother 2009; 53: 316-8.
35. Vilcheze C, Hartman T, Weinrick B et al. Mycobacterium tuberculosis is extraordinarily sensitive to killing by a vitamin C-induced Fenton reaction. Nat Commun 2013; 4: 1881.
36. Cochran WG. Estimation of bacterial densities by means of the "most probable number". Biometrics 1950; 6: 105-16.
37. Garthright WE, Blodgett RJ. FDA's preferred MPN methods for standard, large or unusual tests, with a spreadsheet. Food Microbiol 2003; 20: 439-45.
38. Dunn EA, Roxburgh M, Larsen L et al. Incorporation of triphenylphosphonium functionality improves the inhibitory properties of phenothiazine derivatives in Mycobacterium tuberculosis. Bioorg Med Chem 2014; 22: 5320-8.
39. Matsushita K, Ohnishi T, Kaback HR. NADH-ubiquinone oxidoreductases of the Escherichia coli aerobic respiratory chain. Biochemistry 1987; 26: 7732-7.
40. Benesch RE, Benesch R. Enzymatic removal of oxygen for polarography and related methods. Science 1953; 118: 447-8.
41. Pecsi I, Hards K, Ekanayaka N et al. Essentiality of succinate dehydrogenase in Mycobacterium smegmatis and its role in the generation of the membrane potential under hypoxia. Mbio 2014; 5.
42. Vilcheze C, Weisbrod TR, Chen B et al. Altered NADH/NAD+ ratio mediates coresistance to isoniazid and ethionamide in mycobacteria. Antimicrob Agents Chemother 2005; 49: 708-20.
43. World Health Organization 2014. Antimicrobial Resistance: global report on surveillance. http://www.who.int/drugresistance/documents/surveillancereport/en/.
44. Udwadia Z, Vendoti D. Totally drug-resistant tuberculosis (TDR-TB) in India: every dark cloud has a silver lining. J Epidemiol Community Health 2013; 67: 471-2.
45. Koul A, Dendouga N, Vergauwen K et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 2007; 3: 323-4.
46. Preiss L, Langer JD, Yildiz O et al. Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline. Sci Adv 2015; 1: e1500106.
47. Tahlan K, Wilson R, Kastrinsky DB et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012; 56: 1797-809.
48. Feng X, Zhu W, Schurig-Briccio LA et al. Antiinfectives targeting enzymes and the proton motive force. Proc Natl Acad Sci USA 2015; 112: E7073-82.
49. Grant SS, Kaufmann BB, Chand NS et al. Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals. Proc Natl Acad Sci USA 2012; 109: 12147-52.
50. Weinstein EA, Yano T, Li LS et al. Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs. Proc Natl Acad Sci USA 2005; 102: 4548-53.
51. Yano T, Li LS, Weinstein E et al. Steady-state kinetics and inhibitory action of antitubercular phenothiazines on Mycobacterium tuberculosis type-II NADH-menaquinone oxidoreductase (NDH-2). J Biol Chem 2006; 281: 11456-63.
52. Bettencourt MV, Bosne-David S, Amaral L. Comparative in vitro activity of phenothiazines against multidrug-resistant Mycobacterium tuberculosis. Int J Antimicrob Agents 2000; 16: 69-71.
53. Advani MJ, Siddiqui I, Sharma P et al. Activity of trifluoperazine against replicating, non-replicating and drug resistant M. tuberculosis. PLoS One 2012; 7: e44245.
54. Tommasi R, Brown DG, Walkup GK et al. ESKAPEing the labyrinth of antibacterial discovery. Nat Rev Drug Discov 2015; 14: 529-42.
55. Payne DJ, Gwynn MN, Holmes DJ et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007; 6: 29-40.
56. Brotz-Oesterhelt H, Beyer D, Kroll H-P et al. Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. Nat Med 2005; 11: 1082-7.
57. Cook GM, Greening C, Hards K et al. Energetics of pathogenic bacteria and opportunities for drug development. In: Robert KP, ed. Advances in Microbial Physiology. Academic Press, 2014; 1-62.
58. Rao M, Streur TL, Aldwell FE et al. Intracellular pH regulation by Mycobacterium smegmatis and Mycobacterium bovis BCG. Microbiology 2001; 147: 1017-24.
59. Rao SP, Alonso S, Rand L et al. The proton motive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2008; 105: 11945-50.